3,6-二溴吡嗪-2-甲酸 | 957230-68-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3,6-二溴吡嗪-2-甲酸
• 中文别名: 3，6-二溴吡嗪-2-甲酸
• 英文名称: 3,6-dibromopyrazine-2-carboxylic acid
• CAS: 957230-68-1
• 化学式: C₅H₂Br₂N₂O₂
• 分子量: 281.891
• InChiKey: MJOLIBQBOIULPY-UHFFFAOYSA-N

物化性质

• 沸点：
  368.7±42.0 °C(Predicted)
• 密度：
  2.333±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  3,6-二溴吡嗪-2-甲酸 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 甲苯 、 叔丁醇 为溶剂， 以90 %的产率得到3,6-二溴吡嗪-2-胺
  参考文献：
  名称：

  Dragmacidins G 和 H 的全合成

  摘要：

  使用适当功能化的吡嗪作为底物，通过亲核芳香取代和位点选择性交叉偶联反应，首次实现了德拉马西丁 G 和 H 的全合成。德拉马西丁 G、德拉马西丁 H 和合成类似物对金黄色葡萄球菌和外排泵缺陷型鼠伤寒沙门氏菌的抗菌活性评估表明，靠近硫化物单元的吲哚环上存在 Br 基团对于提高抗菌活性非常重要。

  DOI：

  10.1021/acs.orglett.3c04039
• 作为产物：
  描述：

  3,6-二溴吡嗪-2-甲酸甲酯 在 水 、 sodium hydroxide 作用下， 以 乙腈 为溶剂， 以100 %的产率得到3,6-二溴吡嗪-2-甲酸
  参考文献：
  名称：

  Dragmacidins G 和 H 的全合成

  摘要：

  使用适当功能化的吡嗪作为底物，通过亲核芳香取代和位点选择性交叉偶联反应，首次实现了德拉马西丁 G 和 H 的全合成。德拉马西丁 G、德拉马西丁 H 和合成类似物对金黄色葡萄球菌和外排泵缺陷型鼠伤寒沙门氏菌的抗菌活性评估表明，靠近硫化物单元的吲哚环上存在 Br 基团对于提高抗菌活性非常重要。

  DOI：

  10.1021/acs.orglett.3c04039

文献信息

• FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
  申请人：Andrews Martin James Inglis

  公开号：US20090286798A1

  公开（公告）日：2009-11-19

  Novel[1.2.4]triazolo[1,5-a]pyrazine and imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.

  揭示了具有以下表示的公式的新型[1.2.4]三唑并咪唑[1,2-a]吡嗪化合物：这些化合物可以制备为药物组合物，并可用于哺乳动物包括人类的预防和治疗多种疾病，包括但不限于疼痛、炎症等。
• INHIBITORS OF JAK
  申请人：de Vicente Fidalgo Javier

  公开号：US20110059118A1

  公开（公告）日：2011-03-10

  The present invention relates to the use of novel compounds of Formula I, wherein the variables m, n, p, q, Q, r, R, R′, X, X′, Y, Z 1 , Z 2 , and Z 3 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用式I的新化合物，其中变量m、n、p、q、Q、r、R、R′、X、X′、Y、Z1、Z2和Z3如本文所述定义，这些化合物抑制JAK并且对于治疗自身免疫和炎症性疾病有用。
• FUSED PYRAZINE COMPOUNDS AS THEIR SALTS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
  申请人：WIGERINCK Piet Tom Bert Paul

  公开号：US20110118269A1

  公开（公告）日：2011-05-19

  Novel salts of a [1.2.4]triazolo[1,5-a]pyrazine compound according to Formula I: The salts may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, and others.

  根据公式I，一种[1.2.4]三氮唑[1,5-a]吡嗪化合物的新型盐：这些盐可以制备成药物组合物，并可用于预防和治疗哺乳动物，包括人类的各种疾病条件，例如炎症等。
• Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases
  申请人：Galapagos NV

  公开号：US08012983B2

  公开（公告）日：2011-09-06

  Novel [1.2.4]triazolo[1,5-a]pyrazine and imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.

  本发明揭示了一种具有以下代表性公式的Novel [1.2.4]triazolo[1,5-a]pyrazine和imidazo[1,2-a]pyrazine化合物：这些化合物可以制备为药物组合物，可以用于预防和治疗哺乳动物包括人类的各种疾病，例如但不限于疼痛、炎症等。
• Modulation of Amyloidogenic Protein Self-Assembly Using Tethered Small Molecules
  作者：Emma E. Cawood、Nicolas Guthertz、Jessica S. Ebo、Theodoros K. Karamanos、Sheena E. Radford、Andrew J. Wilson

  DOI：10.1021/jacs.0c10629

  日期：2020.12.9

  Protein-protein interactions (PPIs) are involved in many of life's essential biological functions yet are also an underlying cause of several human diseases, including amyloidosis. The modulation of PPIs presents opportunities to gain mechanistic insights into amyloid assembly, particularly through the use of methods which can trap specific intermediates for detailed study. Such information can also provide a starting point for drug discovery. Here, we demonstrate that covalently tethered small molecule fragments can be used to stabilize specific oligomers during amyloid fibril formation, facilitating the structural characterization of these assembly intermediates. We exemplify the power of covalent tethering using the naturally occurring truncated variant (ΔN6) of the human protein β2-microglobulin (β2m), which assembles into amyloid fibrils associated with dialysis-related amyloidosis. Using this approach, we have trapped tetramers formed by ΔN6 under conditions which would normally lead to fibril formation and found that the degree of tetramer stabilization depends on the site of the covalent tether and the nature of the protein-fragment interaction. The covalent protein-ligand linkage enabled structural characterization of these trapped, off-pathway oligomers using X-ray crystallography and NMR, providing insight into why tetramer stabilization inhibits amyloid assembly. Our findings highlight the power of "post-translational chemical modification" as a tool to study biological molecular mechanisms.